Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAKESH C PATEL

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1295712305
CMS profile
148800
Location
SALISBURY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$4,813.44

185 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,823.17 176
Travel and Lodging $1,969.27 7
Consulting Fee $20.00 1
Education $1.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAKESH C PATEL

NPI 1295712305 · CMS profile ID 148800

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SALISBURY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295712305?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAKESH C PATEL, NPI 1295712305, CMS profile ID 148800. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295712305?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RAKESH C PATEL, NPI 1295712305, CMS profile ID 148800. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295712305?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RAKESH C PATEL, NPI 1295712305, CMS profile ID 148800, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1295712305?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

185 matching records · $4,813.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 185 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–185 of 185.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $14.6103/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691465427 CMS
Novartis Pharmaceuticals Corporation $20.8903/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659905291 CMS
Lilly USA, LLC $12.0303/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658091513 CMS
E.R. Squibb & Sons, L.L.C. $13.8603/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651236975 CMS
Amgen Inc. $11.8603/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662895987 CMS
PFIZER INC. $4.6603/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672124699 CMS
Amgen Inc. $16.0503/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662895971 CMS
UCB, Inc. $20.4203/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688262109 CMS
GlaxoSmithKline, LLC. $20.0003/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670655267 CMS
Janssen Biotech, Inc. $13.9702/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658636143 CMS
PFIZER INC. $9.8202/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672124625 CMS
PFIZER INC. $6.1302/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672124691 CMS
Radius Health, Inc. $16.8202/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683933223 CMS
Amgen Inc. $4.2602/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662895985 CMS
E.R. Squibb & Sons, L.L.C. $15.8102/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651236963 CMS
Genentech USA, Inc. $14.6002/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681266189 CMS
Amgen Inc. $17.5402/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662895981 CMS
Amgen Inc. $11.7102/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662895979 CMS
UCB, Inc. $8.2002/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688250355 CMS
UCB, Inc. $5.8002/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688255383 CMS
UCB, Inc. $2.0402/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688350419 CMS
Lilly USA, LLC $5.6001/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658084989 CMS
PFIZER INC. $14.6001/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671874813 CMS
E.R. Squibb & Sons, L.L.C. $6.6101/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651236961 CMS
Novartis Pharmaceuticals Corporation $18.6201/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659905289 CMS
Genentech USA, Inc. $15.0901/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681234837 CMS
Horizon Therapeutics plc $11.1501/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691465423 CMS
Radius Health, Inc. $17.7001/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683933215 CMS
Lilly USA, LLC $19.3101/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658099245 CMS
Circassia Pharmaceuticals Inc $11.7201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660218629 CMS
Amgen Inc. $15.8201/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662895977 CMS
Hikma Pharmaceuticals USA $14.7301/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688414113 CMS
Sebela Pharmaceuticals Inc. $14.7301/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703870953 CMS
UCB, Inc. $1.6401/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688247475 CMS
UCB, Inc. $7.0201/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688380821 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,813.44 185
PY2020 $1,268.94 80
PY2021 $1,750.51 97
PY2022 $2,044.73 107
PY2023 $2,318.72 122
PY2024 $3,678.58 145
PY2025 $3,003.89 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $110.00 1
PY2025 Principal investigator $779,511.69 85
PY2024 Recipient $25,580.68 3
PY2024 Principal investigator $400,796.41 71
PY2023 Recipient $1,310.83 9
PY2023 Principal investigator $403,240.88 51
PY2022 Recipient $195.00 1
PY2022 Principal investigator $273,585.82 37
PY2021 Principal investigator $536,740.44 76
PY2020 Recipient $223.50 2
PY2020 Principal investigator $670,480.33 93
PY2019 Principal investigator $931,144.93 140

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 12/22/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371969
Principal investigator 1 Janssen Research & Development, LLC $10,166.00 11/28/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371914
Principal investigator 1 Janssen Research & Development, LLC $1,908.00 11/27/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252511
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252789
Principal investigator 1 ABBVIE INC. $5,857.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524964
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18.55 11/20/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235994860
Principal investigator 1 Janssen Research & Development, LLC $250.00 11/20/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251088
Principal investigator 1 Janssen Research & Development, LLC $250.00 11/20/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252660
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,000.00 11/13/2025 Non-covered Recipient Entity
Onsite Clinical Solutions LLC
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220797417
Principal investigator 1 Janssen Research & Development, LLC $166.00 11/10/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371939
Principal investigator 1 ABBVIE INC. $843.08 11/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520911
Principal investigator 1 Janssen Research & Development, LLC $13,000.00 10/27/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371982
Principal investigator 1 Novartis Pharmaceuticals Corporation $44,905.67 10/08/2025 Non-covered Recipient Entity
INTERSPOND, LLC
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190299629
Principal investigator 1 Janssen Research & Development, LLC $162.72 10/03/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371976
Principal investigator 1 Eli Lilly and Company $40.00 09/30/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
Not supplied No dispute reported 06/30/2026 1187887792
Principal investigator 1 Janssen Research & Development, LLC $11,500.00 09/29/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371921
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760151
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760153
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760155
Principal investigator 1 Boehringer Ingelheim International GmbH $131.10 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760157
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760159
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760161
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760163
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760165
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 09/24/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220760167
Principal investigator 1 Janssen Research & Development, LLC $52.00 08/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250492
Principal investigator 1 Janssen Research & Development, LLC $52.00 08/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250764
Principal investigator 1 Janssen Research & Development, LLC $185.00 08/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251178
Principal investigator 1 Janssen Research & Development, LLC $185.00 08/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252699
Principal investigator 1 Janssen Research & Development, LLC $15,800.00 08/28/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371931
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,029.00 08/18/2025 Non-covered Recipient Entity
Interspond, Llc
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235996541
Principal investigator 1 Amgen Inc. $110.05 07/28/2025 Non-covered Recipient Entity
ROWAN DIAGNOSTIC CLINIC, PA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246647480
Principal investigator 1 Janssen Research & Development, LLC $15,800.00 07/28/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371962
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 07/25/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371945
Principal investigator 1 Amgen Inc. $31,144.10 07/23/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS,LLC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246646025
Principal investigator 1 ABBVIE INC. $5,857.00 07/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202497682
Principal investigator 1 Eli Lilly and Company $9,762.00 07/08/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187886866
Principal investigator 1 Janssen Research & Development, LLC $21,600.00 07/04/2025 Non-covered Recipient Entity
ON-SITE CLINICAL SOLUTIONS, LLC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175371955
Principal investigator 1 ABBVIE INC. $843.08 07/02/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202496523
Principal investigator 1 Janssen Research & Development, LLC $185.00 06/30/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175249578
Principal investigator 1 Janssen Research & Development, LLC $52.00 06/30/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251096
Principal investigator 1 Janssen Research & Development, LLC $1,674.00 06/30/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251579
Principal investigator 1 Janssen Research & Development, LLC $52.00 06/30/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251611
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175249475
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250689
Principal investigator 1 Janssen Research & Development, LLC $185.00 05/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252116
Principal investigator 1 Janssen Research & Development, LLC $2,156.00 05/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252844
Principal investigator 1 Janssen Research & Development, LLC $300.00 05/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252853
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252972
Principal investigator 1 Janssen Research & Development, LLC $185.00 05/28/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175253034
Recipient Eli Lilly and Company $110.00 04/04/2025 Covered Recipient Physician AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187872681
Principal investigator 1 Amgen Inc. $280,799.24 04/02/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246642874
Principal investigator 1 ABBVIE INC. $7,737.68 03/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202460824
Principal investigator 1 Janssen Research & Development, LLC $250.00 03/07/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250340
Principal investigator 1 Janssen Research & Development, LLC $250.00 03/07/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252741
Principal investigator 1 Eli Lilly and Company $3,600.00 03/05/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
TALTZ PSA OBSERVATIONAL STUDY No dispute reported 06/30/2026 1187889888
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251330
Principal investigator 1 Janssen Research & Development, LLC $185.00 02/27/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251564
Principal investigator 1 Janssen Research & Development, LLC $1,674.00 02/27/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251663
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252349
Principal investigator 1 Eli Lilly and Company $10,996.00 02/18/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187889104
Principal investigator 1 Amgen Inc. $20,334.66 02/11/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS,LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646028
Principal investigator 1 ABBVIE INC. $2,286.16 02/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202447401
Principal investigator 1 Eli Lilly and Company $18,924.00 01/27/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187890820
Principal investigator 1 Amgen Inc. $25,541.58 01/22/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC SALISBURY
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246646017
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $299.59 01/21/2025 Non-covered Recipient Entity
Onsite Clinical Solutions
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235994862
Principal investigator 1 Eli Lilly and Company $1,679.31 01/16/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187888796
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,543.50 01/15/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190304915
Principal investigator 1 Eli Lilly and Company $1,713.76 01/13/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187887104
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175249251
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175249685
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175249933
Principal investigator 1 Janssen Research & Development, LLC $185.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250023
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250121
Principal investigator 1 Janssen Research & Development, LLC $300.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250213
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250540
Principal investigator 1 Janssen Research & Development, LLC $2,134.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250589
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175250902
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175251813
Principal investigator 1 Janssen Research & Development, LLC $185.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252552
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175252783
Principal investigator 1 Janssen Research & Development, LLC $185.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175253048
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175253206
Principal investigator 1 Eli Lilly and Company $1,535.35 01/09/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187889110
Principal investigator 1 Amgen Inc. $74,055.79 01/08/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS, LLC SALISBURY
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246646020
Principal investigator 1 Eli Lilly and Company $58,141.00 01/07/2025 Non-covered Recipient Entity
ONSITE CLINICAL SOLUTIONS LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187889890